MGMehmet Enes Güner

Mehmet Enes Güner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mehmet Enes Güner has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Subclinical intestinal inflammation in psoriasis: a cross-sectional comparative study using fecal calprotectin

    by Mucahit Marsak, Serpil Sener, Mehmet Enes Güner, Dursun Turkmen, Nihal Altunisik, Zekiye Kanat, Yücel Duman

    Psoriasis is a chronic immune-mediated inflammatory disease driven by dysregulated interactions between keratinocytes and immune pathways, especially the IL-23/Th17 axis. This pathway maintains tis...

  • In-hospital outcomes of SJS/TEN cases in a tertiary center: a 15-year cohort study

    by Dursun Türkmen, Mehmet Enes Güner, Rafet Özbey, Emre Kahraman, Şüheda Ayargil

    Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but severe mucocutaneous adverse drug reactions associated with significant acute mortality and long-term sequelae. Alth...

  • Open Access

    Predictors of Early Response and Relapse in Chronic Spontaneous Urticaria Treated with Omalizumab: The Role of Age, Sex, Disease Duration, and UAS7

    by Mehmet Enes Güner, Perihan Ozturk, Ozan Can Yaray, Esra Merve Evran Kılıç, Mine Müjde Kuş

    Introduction: Omalizumab is an established treatment for chronic spontaneous urticaria (CSU), yet variability in therapeutic response remains a clinical challenge. Identifying baseline predictors of early response may help optimize patient selection and management strategies. Objectives: To evaluate the predictive value of age, sex, baseline disease severity, and disease duration for early response to omalizumab and to assess their relationship with relapse risk. Methods: This retrospective study included 274 patients with CSU treated with omalizumab between 2011 and 2024. Early response was defined as achieving a UAS7 score <7 at one month. Baseline variables included age, sex, UAS7, and disease duration. Binary logistic regression and ROC curve analyses were conducted to identify independent predictors of early response. Results: Among 274 patients (mean age 42.96±15.54 years; 66.4% female), early response was achieved in 37.6%. Early responders had significantly lower baseline UAS7 and shorter disease duration (both P<0.001). Logistic regression confirmed both variables as independent predictors. Age and sex were not independently associated with early response, although univariate analysis showed a higher early response rate in patients aged <45 years. ROC analysis demonstrated strong inverse predictive value for UAS7 (AUC=0.917) and disease duration (AUC=0.940). Relapse risk was significantly lower in females and patients aged <45 years. Conclusions: Lower baseline UAS7 and shorter disease duration independently predict early response to omalizumab. Younger age and female sex may be associated with lower relapse risk. These findings support earlier therapeutic intervention in patients with lower disease burden to improve outcomes.


  • Serum raftlin and 8-isoprostaglandin F2α as potential biomarkers in seborrhoeic dermatitis: a case–control study

    by Mehmet Enes Güner, Ergül Belge Kurutaş, Perihan Öztürk

    Background: Seborrhoeic dermatitis (SD) is a chronic inflammatory skin disorder associated with Malassezia species, immune dysregulation and potential oxidative stress. While previous studies have explored general inflammatory and oxidative mechanisms, specific biomarkers such as raftlin and 8-isoprostaglandin F2α (8-iso-PGF2α) have not yet been investigated in SD. Objectives: To evaluate serum raftlin and 8-iso-PGF2α levels in patients with SD and to determine their relationship with disease severity. Methods: This cross-sectional study included 50 patients with SD and 50 age- and sex-matched healthy controls. Disease severity was assessed using the Seborrheic Dermatitis Area and Severity Index. Serum raftlin and 8-iso-PGF2α levels were measured via the enzyme-linked immunosorbent assay. Statistical analyses included independent-samples t-tests, Spearman correlation and receiver operating characteristic (ROC) curve analysis. Results: Both raftlin and 8-iso-PGF2α levels were significantly higher in patients with SD than in controls (P < 0.001 for both). ROC analysis showed strong discriminatory performance for raftlin (area under the curve 0.987; cutoff 9.30 ng mL−1, 92% sensitivity, 100% specificity) and perfect accuracy for 8-iso-PGF2α (area under the curve 1.000; cutoff 27.9 pg mL−1, 100% sensitivity and specificity). No significant correlation was found between biomarker levels and disease severity. Conclusions: This study demonstrated that serum raftlin and 8-iso-PGF2α levels are significantly elevated in patients with seborrhoeic dermatitis compared with healthy controls. ROC curve analysis indicated strong discriminatory capacity, particularly for 8-iso-PGF2α, which achieved perfect sensitivity and specificity in this cohort. While these biomarkers are not specific to SD and reflect broader inflammatory and oxidative mechanisms, their strong discriminatory ability supports their potential role as adjunctive diagnostic indicators in clinical or research settings. Further validation in larger, multicentre cohorts is warranted to assess their utility across diverse populations and comorbid conditions.


  • Open Access

    Evaluation of the Effects of systemic Therapy on Inflammatory Markers and Disease Severity in Patients With Pemphigus

    by Mehmet Enes Güner, Perihan Ozturk, Mine müjde Kuş

    Introduction: In recent years, various inflammatory markers that can change in inflammatory states have been investigated. On the basis of these, we thought that inflammatory markers could also be used in the treatment of pemphigus disease and monitoring its activity. Objective: In this study, our objective was to investigate changes in the inflammatory markers NLR, PLR, MPV, LMR, CRP and ESR, which are inflammatory markers, before treatment and during follow-up, and the correlation of disease severity with these markers in patients with pemphigus receiving IVIG and/or systemic immunosuppressant agents. Method: 76 pemphigus patients who received systemic treatment, and used these treatments for at least 6 months were included. Changes in NLR, PLR, LMR, MPV, CRP and sedimentation values were examined in patients who received systemic treatment for at least 6 months, before the start of treatment and 3 and 6 months after the start of treatment. Results: Significant changes in inflammatory markers and correlation values were found in all patients. Conclusions: We think that neutrophil, platelet, NLR and PLR values can be used to monitor the response to treatment in pemphigus, since they show a significant decrease with treatment and are significantly positively correlated with PDAI, which indicates the severity of the disease. LMR values were indicators of a poor prognosis. We found that the duration of remission was longer in the group receiving IVIg. Although there was no difference between the treatments in terms of disease recovery, only IVIg prolonged the duration of remission.